Patents Assigned to Entasis Therapeutics Limited
-
Patent number: 10800778Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.Type: GrantFiled: September 15, 2017Date of Patent: October 13, 2020Assignee: Entasis Therapeutics LimitedInventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
-
Patent number: 10376499Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 9, 2018Date of Patent: August 13, 2019Assignee: Entasis Therapeutics LimitedInventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Publication number: 20190202832Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.Type: ApplicationFiled: September 15, 2017Publication date: July 4, 2019Applicants: Entasis Therapeutics Limited, Entasis Therapeutics LimitedInventors: Gregory S. Basarab, Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, Bill Moss, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
-
Patent number: 10238661Abstract: Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2?H,6H-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5?-pyrimidine]-2?,4?,6?(1?H,3?H)-trione, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 27, 2015Date of Patent: March 26, 2019Assignee: Entasis Therapeutics LimitedInventor: Michael Huband
-
Patent number: 9968593Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 17, 2015Date of Patent: May 15, 2018Assignee: Entasis Therapeutics LimitedInventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Patent number: 9839641Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.Type: GrantFiled: November 16, 2016Date of Patent: December 12, 2017Assignee: Entasis Therapeutics LimitedInventors: Gregory Steven Basarab, Madhusudhan Reddy Gowravaram, Sheila Hauck, Fei Zhou
-
Patent number: 9623014Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: GrantFiled: February 29, 2016Date of Patent: April 18, 2017Assignee: Entasis Therapeutics LimitedInventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
-
Patent number: 9540394Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.Type: GrantFiled: October 13, 2015Date of Patent: January 10, 2017Assignee: Entasis Therapeutics LimitedInventors: Gregory Steven Basarab, Madhusudhan Reddy Gowravaram, Sheila Hauck, Fei Zhou
-
Patent number: 9309245Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: GrantFiled: April 2, 2013Date of Patent: April 12, 2016Assignee: Entasis Therapeutics LimitedInventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
-
Patent number: 9187495Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.Type: GrantFiled: October 16, 2014Date of Patent: November 17, 2015Assignee: Entasis Therapeutics LimitedInventors: Gregory Steven Basarab, Madhusudhan Reddy Gowravaram, Sheila Irene Hauck, Fei Zhou